At a Glance
- FibroBiologics secured a Canadian patent for a fibroblast-based cachexia treatment.
- The patent expands the company’s global IP portfolio of 270+ assets.
- The therapy targets inflammation-driven weight and muscle loss in chronic disease.
- Cachexia remains a major unmet need, with a multibillion-dollar market outlook.
Written By: Sana Khan BPharm
Reviewed By: Pharmacally Editorial Team
FibroBiologics, Inc. has strengthened its intellectual property position with the issuance of Canadian Patent No. 3118732, titled “Treatment of Cachexia Using Fibroblast Cells and Products Thereof.” Granted by the Canadian Intellectual Property Office, the patent adds to the company’s portfolio of more than 270 issued and pending patents and supports its strategy of developing fibroblast-based therapies for chronic diseases.
Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics, said the Canadian patent marks an important step in advancing the company’s fibroblast platform and expanding global IP protection as it works toward delivering new treatment options for patients with cachexia.
Cachexia is a complex metabolic syndrome marked by involuntary weight loss, muscle wasting, and persistent inflammation. It commonly affects patients with cancer, HIV/AIDS, and chronic obstructive pulmonary disease, and is linked to poorer outcomes and reduced quality of life. Despite its prevalence, effective treatments remain limited. The cancer-related cachexia market alone is projected to reach about $3.2 billion by 2032.
The newly issued Canadian patent covers methods and compositions for treating cachexia or related inflammatory conditions through the administration of fibroblasts. These cells are cultured under defined conditions to enhance their immune-modulating properties, aiming to suppress inflammatory pathways that contribute to disease progression and to address underlying drivers of cachexia.
A key element of the patent is its focus on fibroblasts capable of reducing inflammatory mediators commonly elevated in cachexia, including C-reactive protein, interleukin-1, interleukin-6, and tumor necrosis factor alpha. By targeting these pathways, the therapy is designed to restore disrupted metabolic and immunological balance.
The patent secures exclusive rights to a proprietary fibroblast cell designed for regenerative and immune-balancing effects, reinforcing the company’s competitive position in cell-based therapies.
In addition, the patent outlines multiple routes of administration, including intravenous, subcutaneous, and intramuscular delivery, providing flexibility in potential clinical use to ameliorate cachexia, prevent further weight loss, or promote weight gain in at-risk patients.
Reference
FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia, 05 February 2026, FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia :: FibroBiologics, Inc. (FBLG)